Spire Wealth Management’s CorMedix CRMD Stock Holding History

Spire Wealth Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.57K	Hold	200	–	–	﹤0.01%	2054
2026 Q1	$1.36K	Hold	200	–	–	﹤0.01%	2097
2025 Q4	$2.33K	Hold	200	–	–	﹤0.01%	2066
2025 Q3	$2.33K	Hold	200	–	–	﹤0.01%	2129
2025 Q2	$2.46K	Hold	200	–	–	﹤0.01%	2137
2025 Q1	$1.23K	Hold	200	–	–	﹤0.01%	2353
2024 Q4	$1.62K	Hold	200	–	–	﹤0.01%	2289
2024 Q3	$1.62K	Hold	200	–	–	﹤0.01%	2036
2024 Q2	$866	Hold	200	–	–	﹤0.01%	2138
2024 Q1	$848	Hold	200	–	–	﹤0.01%	2230
2023 Q4	$652	Hold	200	–	–	﹤0.01%	2328
2023 Q3	$740	Hold	200	–	–	﹤0.01%	2305
2023 Q2	$793	Hold	200	–	–	﹤0.01%	2337
2023 Q1	$828	Hold	200	–	–	﹤0.01%	2407
2022 Q4	$1K	Hold	200	–	–	﹤0.01%	2152
2022 Q3	$1K	Sell	200 -17,000	-99%	-$70.7K	﹤0.01%	2052
2022 Q2	$69K	Hold	17,200	–	–	﹤0.01%	1169
2022 Q1	$94K	Buy	17,200 +6,000	+54%	+$27.5K	﹤0.01%	1183
2021 Q4	$74K	Hold	11,200	–	–	﹤0.01%	1538
2021 Q3	$52K	Buy	11,200 +7,000	+167%	+$40.8K	﹤0.01%	1459
2021 Q2	$29K	Hold	4,200	–	–	﹤0.01%	1715
2021 Q1	$42K	Buy	+4,200	New	+$44.2K	﹤0.01%	1811

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Spire Wealth Management's CRMD Position: Q2 2026 in Review

Spire Wealth Management held its CorMedix (CRMD) position steady in Q2 2026 at 200 shares worth $1.57K. The position accounts for ﹤0.01% of the portfolio, ranked #2054.

Spire Wealth Management first reported a position in CRMD in Q1 2021 and has held it in 22 quarters since. The position peaked at $94K in Q1 2022. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Spire Wealth Management held 200 shares of CorMedix worth $1.57K as of Q2 2026.
Spire Wealth Management left its CorMedix share count unchanged in Q2 2026.
CorMedix made up ﹤0.01% of Spire Wealth Management's portfolio in Q2 2026, its #2054 holding.
Spire Wealth Management first reported a position in CorMedix in Q1 2021 and has held it in 22 quarters since.
Spire Wealth Management's CorMedix position peaked at $94K in Q1 2022.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.